This study examined the pharmacokinetics, pharmacodynamics, and safety of atorvastatin,
an investigational inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) …

Tolerance and pharmacokinetics after single‐dose administration of atorvastatin, an
investigational inhibitor of HMG‐CoA reductase, were examined in 22 healthy volunteers in …

The objective of this study is to determine the relationships between plasma atorvastatin
concentrations, LDL (low‐density lipoprotein) cholesterol reduction, and atorvastatin dose; …

Atorvastatin is a new 3‐hydroxy‐3‐methylglutaryl‐coenzyme A (HMG‐CoA) reductase
inhibitor that reduces plasma cholesterol by inhibiting cholesterol synthesis and increasing …

Background: Atorvastatin is a synthetic inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase. In placebo-controlled trials, it has been shown to achieve significant …

The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, interactions, and
formulary considerations of atorvastatin relative to other hydroxymethylglutaryl-coenzyme A …

This randomized, placebo-controlled, double-masked, parallel-group trial assessed the
serum cholesterol—lowering effects of atorvastatin, a new 3-hydroxy-3-methylglutaryl …

The pharmacodynamic effects and pharmacokinetics of atorvastatin, a potent investigational
inhibitor of HMG‐CoA reductase, were studied in 16 normolipidemic subjects after …

Preclinical and clinical data on atorvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor, indicate that it has superior activity in treating a variety of …

Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease.
Atorvastatin lowers plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of …